| Execution period | Vesting over 3 years; exercise period of 4-5 years |
|---|
BSE filing, NSE: HDFCLIFE. Summary written from the filing by ALFA Finder's alert engine.
HDFC Life Insurance Company Ltd: key numbers
- Share price
- ₹514.10
- Market cap
- ₹1,11,693 Cr
- Revenue (annual)
- ₹99,432 Cr
- Net profit (annual)
- ₹1,912 Cr
- P/E (TTM)
- 54.5×Sector 19.7×
- Promoter holding
- 50.53%-0.01% QoQ
- FII holding
- 18.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from HDFC Life Insurance Company Ltd
All →HDFC Life Insurance Company Annual General Meeting
HDFC Life seeks shareholder approval for an IFSC insurance office at GIFT City, a foreign branch. E-voting runs till November 26, 2026.
- Execution
- E-voting from October 28, 2026 to November 26, 2026
HDFC Life Insurance Company Investor Presentation: Key Takeaways
H1 FY27: VNB ₹2,037 cr (+12%), NBM 24.7%, PAT ₹1,119 cr (+13%), EV ₹66,461 cr, ROEV 14.9%, solvency 180%.
HDFC Life Insurance Company Other Announcement
HDFC Life filed its security cover certificate under Regulation 54(3) for the quarter ended September 30, 2026, confirming its NCDs are unsecured.
HDFC Life Insurance Company Q2 FY27 Results: Net Profit ₹521.6 Cr, Up 16.4% YoY
HDFC Life Insurance Company Ltd reported revenue from operations of ₹409.8 Cr (+13.2% YoY) and net profit of ₹521.6 Cr (+16.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹521.6 Cr · +16.4% YoY
HDFC Life Insurance Company Debt & Borrowing: ₹80.5 Cr
HDFC Life Insurance Company Limited successfully paid Rs. 80.50 Crore in annual interest for its unsecured non-convertible debentures. The payment was completed on October 9, 2026.
- Value
- ₹80.50 Cr
HDFC Life Insurance Company Debt & Borrowing: ₹3,099 Cr
HDFC Life Insurance disclosed its outstanding privately placed non-convertible debentures as of September 30, 2026, in compliance with SEBI circular requirements.
- Value
- ₹3,099 Cr
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.